Monaco Asset Management SAM acquired a new position in Inogen, Inc. (NASDAQ:INGN – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 75,000 shares of the medical technology company’s stock, valued at approximately $610,000.
Several other large investors have also recently modified their holdings of INGN. Jump Financial LLC grew its holdings in shares of Inogen by 153.0% during the 4th quarter. Jump Financial LLC now owns 39,728 shares of the medical technology company’s stock worth $218,000 after acquiring an additional 24,028 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Inogen during the 4th quarter worth approximately $189,000. Olympiad Research LP purchased a new position in shares of Inogen during the 4th quarter worth approximately $97,000. PNC Financial Services Group Inc. grew its holdings in shares of Inogen by 2,918.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company’s stock worth $43,000 after acquiring an additional 7,646 shares during the period. Finally, Quadrature Capital Ltd grew its holdings in shares of Inogen by 106.4% during the 4th quarter. Quadrature Capital Ltd now owns 31,071 shares of the medical technology company’s stock worth $171,000 after acquiring an additional 16,017 shares during the period. Hedge funds and other institutional investors own 89.94% of the company’s stock.
Inogen Price Performance
NASDAQ:INGN opened at $11.33 on Tuesday. The firm has a market capitalization of $268.75 million, a price-to-earnings ratio of -2.73 and a beta of 1.05. Inogen, Inc. has a one year low of $4.13 and a one year high of $13.33. The business has a fifty day moving average price of $10.44 and a 200-day moving average price of $8.65.
Analyst Ratings Changes
INGN has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Wednesday, August 7th. StockNews.com raised Inogen from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Inogen has an average rating of “Hold” and an average price target of $7.00.
View Our Latest Research Report on INGN
Inogen Profile
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Recommended Stories
- Five stocks we like better than Inogen
- How to Invest in the Best Canadian Stocks
- How the Fed’s Rate Cuts Could Boost Bonds, Silver, and Small Caps
- Where Do I Find 52-Week Highs and Lows?
- Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long
- How Can Investors Benefit From After-Hours Trading
- Top 3 Small-Cap Stocks Insiders Are Buying Right Now
Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc. (NASDAQ:INGN – Free Report).
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.